Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Grifols' AMBAR approach slows disease progression in moderate Alzheimer’s

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) reported Phase IIb/III data on its AMBAR approach to treat Alzheimer’s disease demonstrating evidence of mechanism and improvements in clinical outcomes.

AMBAR, which stands for Alzheimer Management by Albumin Replacement, was designed

Read the full 354 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE